Schütte, Moritz
Risch, Thomas
Abdavi-Azar, Nilofar
Boehnke, Karsten
Schumacher, Dirk
Keil, Marlen
Yildiriman, Reha
Jandrasits, Christine http://orcid.org/0000-0003-1357-4401
Borodina, Tatiana
Amstislavskiy, Vyacheslav http://orcid.org/0000-0002-1384-7599
Worth, Catherine L.
Schweiger, Caroline
Liebs, Sandra
Lange, Martin http://orcid.org/0000-0002-4045-3915
Warnatz, Hans- Jörg
Butcher, Lee M.
Barrett, James E.
Sultan, Marc
Wierling, Christoph
Golob-Schwarzl, Nicole
Lax, Sigurd
Uranitsch, Stefan
Becker, Michael
Welte, Yvonne
Regan, Joseph Lewis
Silvestrov, Maxine
Kehler, Inge
Fusi, Alberto
Kessler, Thomas
Herwig, Ralf http://orcid.org/0000-0002-9335-1760
Landegren, Ulf http://orcid.org/0000-0002-7820-1000
Wienke, Dirk
Nilsson, Mats
Velasco, Juan A.
Garin-Chesa, Pilar
Reinhard, Christoph
Beck, Stephan http://orcid.org/0000-0001-5290-2151
Schäfer, Reinhold
Regenbrecht, Christian R. A.
Henderson, David
Lange, Bodo
Haybaeck, Johannes http://orcid.org/0000-0001-5518-3359
Keilholz, Ulrich
Hoffmann, Jens
Lehrach, Hans
Yaspo, Marie-Laure http://orcid.org/0000-0002-9555-9979
Article History
Received: 14 June 2016
Accepted: 13 December 2016
First Online: 10 February 2017
Competing interests
: Several of the authors are employees of the following pharmaceutical companies: Eli Lilly (K.B., J.V., C. Reinhard), Merck KGaA (D.W.), Boehringer Ingelheim (P.G.-C.), and Bayer-Pharma (D.H., M.L.). Other authors are employees of Alacris Theranostics (B.L. (CEO), M. Schütte, R.Y., C.W., T.B., T.K.), founder of Alacris Theranostics (H.L.), founder and CEO of cpo (C.R.A.R.), employees or shareholders of cpo (Y.W., M. Silvestrov, R.S., J. Hoffmann), employee and/or shareholder of EPO (J. Hoffmann,M.K.). None of these companies influenced the interpretation of the data, or the data reported, or financially profit by the publication of the results. The remaining authors declare no competing financial interests.